Status:
COMPLETED
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells
Lead Sponsor:
Red de Terapia Celular
Collaborating Sponsors:
Citospin
University of Valladolid
Conditions:
COVID-19 Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Novel coronavirus disease COVID-19, produced by SARS-CoV-2, has become a health emergency around the world. Since first patients were detected in Wuhan (China), in December 2019, COVID-19 has spread q...
Detailed Description
Novel coronavirus disease COVID-19, produced by SARS-CoV-2, has spread quickly from Wuhan (China) to worldwide. On April 15, 2020, the World Health Organization (WHO) has reported 1.914.916 confirmed ...
Eligibility Criteria
Inclusion
- Women or men of ≥ 18 years of age
- SARS-CoV-2 infection confirmed by molecular testing.
- Admitted to the Intensive Care Unit with pneumonia by COVID-19 infection and intubated in the last 48 hours, that meet at least one of these criteria:
- Respiratory distress.
- Respiratory rate (RR) ≥ 30 rpm.
- Basal oxygen saturation at rest ≤ 93%.
- Arterial partial pressure of oxygen (PaO2) / inspiratory fraction of oxygen (FiO2) ≤ 300 mmHg.
- Consent of the patient or his/her legal representative for participation in the study.
Exclusion
- Active tumor disease.
- Pregnancy.
- Participation in another active clinical trial.
- Any circumstance that in the researcher's opinion justifies the patient's non-participation in the trial.
- Not consent to participation.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 28 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04361942
Start Date
May 1 2020
End Date
October 28 2021
Last Update
February 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Rio Hortega
Valladolid, Spain, 47012